A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Merck Sharp & Dohme LLC
3D Medicines
Merck Sharp & Dohme LLC
ETOP IBCSG Partners Foundation
Salubris Biotherapeutics Inc
Medical University Innsbruck
The University of Hong Kong
Eisai Inc.
Eisai Inc.